New data shows high barrier pharmaceutical packaging films market in Europe and globally is growing strongly, driven by stringent regulatory demands and rising drug safety standards.

Regulatory demands and drug quality standards are fueling robust market expansion for high barrier pharmaceutical blister packaging films.

Sichuan Biokin Pharmaceutical pursues a $432 million Hong Kong listing to expand R&D and global manufacturing capabilities, with strategic backing from major investors.

The EU is in the decisive stage of a sweeping pharmaceutical law reform aimed at boosting industry competitiveness, improving supply chain resilience, addressing shortages, and accelerating digital transformation.

The US government and Eli Lilly/Novo Nordisk reached a pivotal agreement today to drastically lower GLP-1 drug prices, expand Medicare/Medicaid access, and incentivize new domestic manufacturing projects.

Clariant has completed a CHF 80-million expansion of its Daya Bay, China, facilities, strengthening pharmaceutical excipients and specialty chemicals manufacturing for Asia.

Hikma Pharmaceuticals updates 2025 growth guidance and restructures global R&D to drive manufacturing and pipeline expansion in Europe.

Johnson & Johnson has gained US FDA approval to market Caplyta as a treatment for depression, strengthening its neuropsychiatric portfolio and commercial strategy.

HUTCHMED has completed patient enrollment for its global Phase III trial of ORPATHYS® and TAGRISSO® in advanced NSCLC, advancing a pivotal chemotherapy-free option across Asia-Pacific.

Moberg Pharma and Karo Healthcare finalize a pan-European licensing deal for MOB-015 (Terclara®), targeting coordinated launches and market leadership in antifungal therapy.